Welcome to QBiotics

An Australian naturally inspired life sciences company

Human Health
Animal Health
Investor Health

UPDATES


QBiotics doses first Australian patient in Phase I/II clinical trial for head and neck cancer

22 July 2020

First Australian patient successfully dosed with tigilanol tiglate at The Kinghorn Cancer Centre, as part of QBiotics’ Phase I/II clinical trial in patients with Head and Neck Squamous Cell Carcinoma (HNSCC).


Pivotal canine field study results published in The Journal of Veterinary Internal Medicine reveal STELFONTA® (tigilanol tiglate) removes 75% of tumours

17 June 2020

The study of 123 client-owned dogs demonstrated that in those with Mast Cell Tumours (MCTs), a single intratumoural injection of STELFONTA® removed 75% of MCTs at day 28, significantly higher compared to untreated controls (p<0.001). Further, the trial showed no recurrence in 93% of STELFONTA®-treated dogs at day 84.


QBiotics commercialises first tigilanol tiglate pharmaceutical product with launch of STELFONTA®

27 April 2020

Australian life sciences company, QBiotics Group Limited (QBiotics) has commercialised the first product for its lead compound, tigilanol tiglate, with the launch of STELFONTA® in the European markets at the Virbac Oncology Summit Webinar Event (24 April 2020).


QBiotics raises AU$17.76 million from Sophisticated Investors

February 2020

Australian life sciences company, QBiotics Group Limited (QBiotics), has completed a share placement to Sophisticated Investors with a total of AU$17,756,150 raised.  The Board authorised and approved the issue and allotment of 25,365,929 Shares at an issue price of AU$0.70 per Share to the subscribers under the Offer.


QBiotics receives first registration for tigilanol tiglate with European Medicines Agency approval of STELFONTA®

20 January 2020

STELFONTA® (tigilanol tiglate) has been approved by the European Medicines Agency (EMA), making it the first pharmaceutical treatment available for all grades of canine non-metastatic mast cell tumours (MCT). The approval marks the first registration of QBiotics' lead compound tigilanol tiglate, which is also under review by the US Food and Drug Administration - Center for Veterinary Medicine (FDA-CVM) and the Australian Pesticides and Veterinary Medicines Authority (APVMA).


The first in-human Clinical Phase I study of intratumoural tigilanol tiglate has been published in The Lancet's EBioMedicine journal

10 December 2019

An efficacious dose was achieved and a Maximum Tolerated Dose (MTD) was not reached, indicating tigilanol tiglate tolerability in humans. Promising outcomes were attained in patients with a variety of solid tumour types, with a 27% treatment response, including 18% complete response (full tumour destruction). Following these positive results, a Phase I/II trial of tigilanol tiglate in patients with Head and Neck Squamous Cell Carcinoma (HNSCC) is underway, with the first patient successfully dosed.